TG Therapeutics Inc (TGTX)

[stockguard]

TG Therapeutics (TGTX)

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on TG Therapeutics, with a price target of $20. The company’s shares closed yesterday at $4.80, close to its 52-week low of $3.32.

White said:

“Our $20 price target is based on the net present value of our revenue forecast through 2027, applying a 40% probability of success (POS) for ublituximab in CLL, a 40% POS for umbralisib in CLL, a 25% POS for both ublituximab and umbralisib in 40% POS for ublituximab in MS. We use a 4x price/sales multiple for these products and an early stage pipeline value of $0.23/share, which includes an anti-PD-L1 drug, and oral BTK inhibitor, and a CD47/CD19 bi-specific antibody, to arrive at our price target. Our P/S multiple of 4x is in-line with TG’s peers that range between 2-5x.”

https://www.markets.co/analysts-offer-insights-on-healthcare-companies-ocular-therapeutix-nasdaq-ocul-agile-therapeutics-nasdaq-agrx-and-tg-therapeutics-nasdaq-tgtx/199327/